Table 2. Details of mutations found according to antiretroviral family and period of study.
| Period | |||||
|---|---|---|---|---|---|
| Mutations N (%)* | total | 1997–2000 | 2001–2004 | 2005–2008 | 2009–2012 |
| 189 | 28 | 42 | 55 | 64 | |
| NRTI | |||||
| M41L | 6 (3.2) | 2 (7.1) | 2 (4.8) | 0 (0) | 2 (3.1) |
| D67N | 3 (1.6) | 1 (3.6) | 0 (0) | 1 (1.8) | 1 (1.6) |
| T69N | 2 (1.1) | 1 (3.6) | 0 (0) | 0 (0) | 1 (1.6) |
| K70R | 2 (1.1) | 2 (7.1) | 0 (0) | 0 (0) | 0 (0) |
| M184V | 1 (0.5) | 1 (3.6) | 0 (0) | 0 (0) | 0 (0) |
| L210W | 3 (1.6) | 1 (3.6) | 1 (2.4) | 1 (1.8) | 0 (0) |
| T215F/Y | 3 (1.6) | 2 (7.2) | 1 (2.4) | 0 (0) | 0 (0) |
| T215S/D/L | 2 (1.1) | 0 (0) | 0 (0) | 2 (3.6) | 0 (0) |
| K219E/Q | 4 (2.2) | 2 (7.2) | 0 (0) | 1 (1.8) | 1 (1.6) |
| NNRTI & | |||||
| K101E | 1 (0.5) | 0 (0) | 1 (2.4) | 0 (0) | 0 (0) |
| K103N | 3 (1.6) | 1 (3.6) | 1 (2.4) | 0 (0) | 1 (1.6) |
| Y181C | 3 (1.6) | 1 (3.6) | 1 (2.4) | 1 (1.8) | 0 (0) |
| G190A | 1 (0.5) | 0 (0) | 1 (2.4) | 0 (0) | 0 (0) |
| PI | |||||
| M46I/L | 5 (2.7) | 2 (7.1) | 2 (4.8) | 0 (0) | 1 (1.6) |
| I54L | 1 (0.5) | 1 (3.6) | 0 (0) | 0 (0) | 0 (0) |
| V82A/F/I/T | 7 (3.7) | 3 (1.6) | 2 (4.8) | 0 (0) | 2 (3.1) |
| L90M | 2 (1.1) | 0 (0) | 1 (2.4) | 1 (1.8) | 0 (0) |
* Only mutations found in at least one case according to WHO list of TDR are listed.
& E138A mutation, not listed by WHO 2009 list but associated to rilpivirine resistance was detected in 4 patients (2.1%), 3 (5.4%) in the 2005–2008 period and 1 (1.6%) in the 2009–2012 period.
NRTI: Nucleoside/nucleotide reverse transcriptase inhinitors
NNRTI: Non-nucleoside reverse transcriptase inhibitors
PI: Protease inhibitors